ORIC reports strong Phase 1b results for enozertinib and plans 2027 Phase 3 trial

ORIC Pharmaceuticals presented Phase 1b data for its brain‑penetrant EGFR inhibitor enozertinib in first‑line NSCLC patients with atypical EGFR mutations. The study showed an 84% systemic objective response rate and a 70% intracranial response rate, with 65% of patients having baseline brain metastases. The company announced a global Redwood‑1 Phase 3 registrational trial to begin in the first half of 2027, targeting about 360 patients and using dual primary endpoints of ORR and progression‑free survival. Safety was favorable, with only 23% of patients experiencing Grade 3 treatment‑related adverse events and no Grade 4‑5 events.

The data move enozertinib into late‑stage development, positioning ORIC to capture a U.S. market opportunity estimated at over $2.5 billion for first‑line atypical EGFR NSCLC (the company says). The upcoming Phase 3 trial will determine whether the drug can achieve accelerated approval and generate significant revenue if successful.

  • 1Systemic ORR was 84% by investigator assessment (84% of 26 patients).
  • 2Intracranial ORR was 70% by investigator assessment.
  • 3Baseline brain metastases were present in 65% of patients, including 46% untreated.
  • 4Six‑month landmark PFS rate was 88% (median PFS immature).
  • 5Grade 3 treatment‑related adverse events occurred in six patients (23%).
  • 6Redwood‑1 Phase 3 trial is planned for the first half of 2027 and will enroll approximately 360 patients.

Sources